

Anaerobe Cumulative Antibiogram	Ampicillin/sulbactam	Cefoxitin	Clindamycin	Meropenem	Metronidazole	Moxifloxacin	Piperacillin/tazobactam
<i>Bacteriodes fragilis</i>	84	100	26	93	100	61	96
<i>Prevotella species</i>	97	—	69	98	99	66	100
<i>Fusobacterium species</i>	100	—	77	100	95	68	96
Anaerobic gram- positive cocci	—	—	97	100	100	72	99
<i>Cutibacterium acnes</i>	—	—	53	—	0	95	100
<i>Clostridium perfringens</i>	100	—	83	100	100	83	100
<i>Clostridium species</i> (not perfringens)	—	—	67	100	100	62	94

Reference:
CLSI M100 35th edition
Isolates collected from selected US hospitals from Jan. 1, 2013,
to Dec. 31, 2016.

Common Indications for Empiric Vancomycin

- Febrile Neutropenia**
- High risk (refer to NCCN or IDSA guidelines for criteria) with severe cephalosporin allergy
 - Suspected serious catheter-related infection, SSTI, pneumonia, hemodynamic instability, blood culture with gram-positive cocci, or previous MRSA infection/colonization

- Community-Acquired Pneumonia (CAP)**
- Severe CAP (ie: admitted to ICU) PLUS hospitalized with IV antibiotics within prior 90 days
 - Prior respiratory isolation of MRSA

- Hospital-acquired (HAP)/ventilator-associated (VAP) Pneumonia**
- Prior respiratory isolation of MRSA
 - Empyema
 - Risk factors for resistance or mortality
 - HAP: mechanical ventilation, septic shock, IV antibiotics within 90 days
 - VAP: acute respiratory distress syndrome prior to VAP, septic shock at time of VAP, IV antibiotics within 90 days, acute renal replacement therapy prior to VAP, ≥ 5 days in hospital prior to VAP

- Skin and Soft Tissue Infection (SSTI)**
- Severe purulent infection or presence of abscess
 - Non-purulent infection with one of the following:
 - Severe cephalosporin allergy
 - MRSA risk (penetrating trauma, MRSA infection elsewhere or nasal colonization, injection drug use, severely immunocompromised)
 - Necrotizing fasciitis
 - ICU admission for SSTI

- Diabetic Foot Infection (DFI)/Chronic Wound**
- Any indications listed within SSTI section
 - Severe or chronic-moderate
 - Moderate: deeper than skin & subcutaneous tissues, no signs of systemic inflammatory response syndrome (SIRS)
 - Severe: SIRS OR presence of ischemia
 - ICU admission for DFI or chronic wound



SMH Levofloxacin Guidelines for Use

- CAP when B-lactam allergy present
- HAP/VAP: As 2nd agent if dual pseudomonas coverage indicated
- Acute exacerbation of COPD
- MDR organism
- Pseudomonas if po agent needed
- UTI when B-lactam allergy present (acute uncomplicated cystitis in women)
- UTI if complicated/male
- Prostatitis
- Pyelonephritis step-down
- Gram-negative (excluding pseudomonas) bacteremia step-down if po agent needed
- Intra-abdominal infection
- Uncomplicated febrile neutropenia
- Leukemia antibiotic prophylaxis
- Surgical prophylaxis if B-lactam allergy

2025

Antimicrobial Agent
Susceptibilities

PROVIDED BY

Microbiology **Pharmacy**
217-788-3057 217-788-3010



701 N. First St. • Springfield, IL 62781

Jan. 1–Dec. 31, 2024 Inpatient isolates only, first isolate per patient	Percent Susceptible — All Inpatients																																					
	# Isolates	Ampicillin (\$\$\$ - IV) (\$ - PO)		Ampicillin/sulbactam (\$\$)		Cefepime (\$\$)		Ceftazidime (\$\$)		Ceftriaxone (\$)		Clindamycin (\$\$ - IV) (\$ - PO)		Erythromycin (\$)		Gentamicin (\$\$)		Levofloxacin (\$ - IV) (¢ - PO)		Linezolid (\$\$ - IV) (\$ - PO)		Meropenem (\$\$\$)		Nitrofurantoin (\$)		Oxacillin (\$\$)		Penicillin-G (\$\$)		Piperacillin-Tazobactam (\$\$)		Tetracycline		TMP/SMX (\$\$ - IV) (¢ - PO)		Tobramycin (\$)		Vancomycin (\$\$)
GRAM NEGATIVE BACILLI	Percent Susceptible																																					
<i>Escherichia coli</i>	921	52	64		95	89	R		92	73			97	R	R	R	94		80	93	R																	
<i>Klebsiella pneumoniae</i>	342	R	82		93	90	R		95	88			30	R	R	R	97		91	93	R																	
<i>Klebsiella oxytoca</i>	117	R	77	100	100	94	R		97	96			83	R	R	R	95		95	97	R																	
<i>Proteus mirabilis</i>	261	80	91		100	95	R		95	76			R	R	R	R	100	R	85	95	R																	
<i>Enterobacter cloacae</i>	137	R	R	100			R		99	91				R	R				96	99	R																	
<i>Enterobacter aerogenes</i>	58	R	R	98			R		95	90			22	R	R				91	93	R																	
<i>Serratia marcescens</i>	57	R	R	100	100	96	R		100	93			R	R	R				98	91	R																	
<i>Citrobacter freundii</i>	45	R	R	100			R		93	82			88	R	R				89	96	R																	
<i>Morganella morganii</i>	39	R	R	100	85	87	R		97	76			R	R	R	R	100		82	100	R																	
<i>Pseudomonas aeruginosa</i>	400	R	R	89	90	R	R			77		93		R	R	R	79	R	R	97	R																	
<i>Acinetobacter baumannii</i>	38	R	66	45	53		R		79	55		55		R	R		50		71	74	R																	
<i>Stenotrophomonas maltophilia</i>	57	R	R			R	R		R	95		R		R	R	R	R		93	R	R																	
GRAM POSITIVE COCCI	Percent Susceptible																																					
<i>Staphylococcus aureus</i> §	654	R					74	41			100			52				87	98		100																	
<i>Staphylococcus aureus</i> (MRSA)	321	R					67	14			100			0				81	97		100																	
<i>Staphylococcus aureus</i> (MSSA)	356	R					80	67			100			100				93	99		100																	
<i>Staphylococcus epidermidis</i>	153	R					52	25			100			30				71			100																	
<i>Staphylococcus lugdunensis</i>	46	R					60	60			100			74				87			100																	
<i>Enterococcus faecalis</i>	164	99		R	R	R	R				100								R	R	94																	
<i>Enterococcus faecium</i>	73	7		R	R	R	R				100								R	R	18																	
<i>Streptococcus agalactiae</i>	41	100				100	50			100						100					100																	
<i>Streptococcus pyogenes</i> *	40	100				100										100					100																	
<i>Streptococcus pneumoniae</i>	31					90†										68†																						
						100‡		54		100						100‡			76		100																	

Jan. 1–Dec. 31, 2024 ICU isolates only, first isolate per patient	Percent Susceptible — ICU																				
	# Isolates	Ampicillin	Ampicillin/sulbactam	Cefepime	Ceftazidime	Ceftriaxone	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Meropenem	Nitrofurantoin	Oxacillin	Penicillin-G	Piperacillin-Tazo	Tetracycline	TMP/SMX	Tobramycin	Vancomycin	
	Percent Susceptible																				
	<i>Escherichia coli</i>	118	38	58		92	86	R		92	68			99	R	R	94		80	91	R
	<i>Klebsiella pneumoniae</i>	63	R	81		92	89	R		98	86				R	R	96		93	97	R
	<i>Proteus mirabilis</i>	25	60	92		100	88	R		92	56			R	R	R	100	R	80	96	R
	<i>Enterobacter cloacae</i>	25	R	R	96			R		100	92				R	R			96	100	R
	<i>Pseudomonas aeruginosa</i>	54	R	R	87	89	R	R			78		93		R	R	78	R	R	94	R
	<i>Acinetobacter baumannii</i>	11	R	91	73	64		R		91	73		73		R	R	64		91	91	R
	Percent Susceptible																				
<i>Staphylococcus aureus</i> [§]	102	R					75	50			100			51			88	99		100	

KEY

* Combined isolates from 2021–2024

R Intrinsic resistance

§ First staphylococcus aureus isolate per patient

† Meningitis interpretations

‡ Non-meningitis interpretations

COST

¢ < \$1

\$ = \$1–\$10

\$\$ = \$10–\$50

\$\$\$ = \$50–\$100

\$\$\$\$ = \$100–\$200

\$\$\$\$\$ > \$200